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Abstract 
 
 
Objectives  
Alterations in dopamine (DA) neurotransmission underlie some of the clinical features of 
Huntington’s disease (HD) and as such are a target for therapeutic intervention, especially for the 
treatment of chorea and some behavioural problems. However, justification for such an intervention is 
mainly based on case reports and small open label studies and the effects these drugs have on 
cognition in HD remains unclear.  
 
Methods 
In this study, we used the Enroll-HD observational database to assess the effects of antidopaminergic 
medication on motor, psychiatric and cognitive decline, over a 3- year period. We first looked at the 
annual rate of decline of a group of HD patients taking antidopaminergic medication (n=466) 
compared to an untreated matched group (n=466). The groups were matched on specified clinical 
variables using propensity score matching. Next, we studied a separate group of HD patients who 
were prescribed such medications part way through the study (n=90) and compared their rate of 
change before and after the drugs were introduced and compared this to a matched control group.  
 
Results 
We found that HD patients taking antidopaminergic medication had a slower progression in chorea 
and irritability compared to those not taking such medications. However, this same group of patients 
also displayed significantly greater rate of decline in a range of cognitive tasks.  
 
Conclusion 
In conclusion we found that antidopaminergic treatment is associated with improvements in the 
choreic movements and irritability of HD but worsens cognition. However, further research is 
required to prospectively investigate this and whether these are causally linked, ideally in a double-
blind placebo-controlled trial.  
 
Introduction  
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by an 
expanded CAG repeat in the HTT gene (mHTT) on chromosome 4. Involuntary movements are a 
classical feature of HD although cognitive and psychiatric impairments along with other neurological 
changes are also a prominent early feature of the disease and place significant burden on patients and 
their families. Cognitive deficits include a loss of higher-order ‘executive functions’ such as attention, 
planning, flexibility and memory [1-2], as well as compromised emotional processing [3] and 
visuospatial perception [1]. In more advanced stages an overall cognitive decline is observed leading 
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to dementia in the majority of patients. Psychiatric impairments including irritability, obsessive and 
perseverative behaviours, apathy and depression [4-6] are evident at all stages of the disease [7-8].  
 
HD is defined pathologically by the dysfunction and subsequent loss of neurons, most notably, in 
early stage disease, in the striatum and cortex [9-10] – areas which receive a significant 
dopaminergic input [11]. Paradoxically, while there is an early loss of postsynaptic dopamine 
receptors at these sites, one of the most effective and widely used therapies involves dopamine 
blocking/depleting agents especially for the chorea [6]. However, the empirical evidence for this 
approach is lacking. Only tetrabenazine has been subjected to formal efficacy trials, and its use is 
associated with an increased risk of depression and anxiety [12]. 
 
It is well known that in addition to its role in motor function, DA is also critical for higher-order 
cognitive processes, in particular executive function [13] as well as psychiatric symptomatology such 
as psychosis, motivating effortful behaviour, reinforcement learning and reward processing [14-15]. 
Regarding cognitive function, it has been postulated that DA modulates this in an inverted U function 
fashion, whereby both excessive and insufficient cortical levels perturb performance [16]. Therefore, 
aberrant dopamine signalling may also contribute to the cognitive disturbances in HD, although this 
has not been well studied [17]. It is thus possible that antidopaminergic treatment targeted at the 
motor impairments of HD also have an impact on non-motor features of the disease.  
 
We therefore sought to investigate the effect of antidopaminergic medication on motor, cognitive and 
psychiatric decline in HD using the Enroll-HD database. We found that the introducing these 
medications was associated with improvements in chorea and irritability but a decline in cognition. 
 
Methods  
 
In this study, data was analysed from the CHDI Foundation Enroll-HD study (https://www.enroll-
hd.org). Enroll-HD is a longitudinal, observational, multinational study of HD gene carriers who 
undergo an annual appointment which includes a review of current medication and a battery of motor, 
cognitive and psychiatric assessments. Our analysis was performed on the 4th data cut comprising 
15,302 participants with an average of 2.4 visits (ranging from 1-6 visits). In the study, motor features 
are scored using the Unified Huntington Disease Rating Scale (UHDRS’99; Huntington Study Group, 
1996). Psychiatric features are assessed using the Problems Behavioural Assessment (PBA) and the 
depression, irritability and apathy sub-scores from this were used in the current study. Cognitive 
assessments include the Symbol Digit Modalities Test (SDMT), Phonemic Verbal Fluency, Stroop 
and Trail Making tasks [18]. In the current paper, we assign a composite ‘total cognitive score’ for 
each individual by transforming the raw scores for each cognitive task into z-scores (z = (x – μ) / σ) 
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and adding them together to create a single z-score per patient. When calculating z-scores, the two 
groups (antidopaminergic medication takers and non- antidopaminergic medication takers, outlined in 
detail below) were pooled together in order to calculate the population mean and standard deviation. 
Results for individual cognitive task scores are found in the supplementary section.  
 
Data analysis 
The data was filtered to include only manifest HD patients, over the age of 18, with a CAG repeat 
length of 36-55, (n= 8004). Participants with at least two complete visits (n= 5011) were sorted into 
two groups, those taking antidopaminergic medication during the period of data collection (n=2369), 
and those not taking antidopaminergic medication for the entire period (n=2642). Next, propensity 
score matching was performed, whereby the two groups were matched for age, CAG repeat length, 
TFC score and time since diagnosis using the ‘match it’ plugin for R statistical software. The ‘nearest 
neighbour’ matching command was used, which selected the most closely matched control for each 
participant in the antidopaminergic medication group (n=466 per group). 	 	
We also investigated whether those starting antidopaminergic medication part way through the study 
exhibited changes in the rate of motor, cognitive and psychiatric decline following medication 
introduction. Individuals with at least two visits prior to taking antidopaminergic medication and two 
visits whilst taking the medication (n= 90) were included. Again, we used propensity score matching 
to match these individuals with a clinically comparable control group to give an indication of the 
average change in score for each assessment over the same four-year period. Table 1 outlines the 
antidopaminergic medications included in the analysis. 
 
Statistical analysis 
 
Baseline demographics between treatment and control groups were compared using t-tests. For 
multivariate analyses, parametric methods were used due to there being a sufficiently large sample 
size. The annual change in score for each assessment was calculated for every patient and their 
average score for each assessment across visits was taken. The point change in cognitive, motor or 
psychiatric performance for each participant was calculated by subtracting the first assessment score 
from the last assessment score. A patient’s average score for each assessment across visits was then 
taken. 
 
Group 1: HD antidopaminergic takers (n= 466) and HD controls (non- antidopaminergic takers) (n= 
466) 
For each assessment, the average rate of change of the two groups was compared using a univariate 
ANOVA with change in score as the dependent variable, group (antidopaminergic medication takers 
 5 
versus non- antidopaminergic medication takers) as the independent variable and age, CAG repeat 
length and gender as covariates. The resulting p- values were then corrected for multiple comparisons 
(and the associated risk of Type 1 errors), using the False Discovery Rate (FDR) method, with a 
threshold set at 5% (q<0.05). To assess which factors predict the annual change in composite 
cognitive score, a multivariate linear regression was used with the addition of the following variables: 
group, CAG repeat length, gender, age, DBS, TFC, time since diagnosis, UHDRS motor score, 
depression, apathy, and irritability scores. Psychiatric measures were included as they can affect 
cognitive abilities, likely due to a variety of factors including anhedonia, decreased motivation, 
concentration difficulties and impairments in attention and processing speed [19].  
 
In addition to using propensity score matching, we verified our results using covariate adjustment, 
based on the findings by Elze et al., 2017 [20], which showed that this more conventional technique 
may be the most reliable method for the analysis of observational databases. To do this, we compared 
the yearly rate of change between the group taking antidopaminergic medication (n= 2369) and the 
group of non-takers (n=2642) using a univariate ANOVA with the following covariate variables: age, 
gender, CAG repeat length, DBS, TFC and time since diagnosis (see supplementary section). 
DBS = (CAG – 35.5)*age [21]. 
 
Group 2: HD pre- and post-antidopaminergic takers (n= 90) and HD controls (non- 
antidopaminergic takers) (n= 104) 
These patients had completed four annual assessments, the antidopaminergic subgroup being on 
medication for the last two assessments only. The rate of change between the first and second year 
(referred to as time interval 1) was compared with the rate of change between the third and fourth 
years (time interval 2), using paired t-tests, for both groups separately. Then, for each time interval, 
the rate of decline of the two groups was compared with a univariate ANOVA with change in score as 
the dependent variable, group as the independent variable and age, CAG repeat length and gender as 
covariates. Graphpad Prism software and IBM SPSS statistics v25 were used to conduct the statistical 
analysis 
 
Table 1: List of antidopaminergic medication included in the current analysis  
 
Drug Number of patients on each drug  
 Group 1 
(n=466*) 
Group 2  
(n=90*) 
On two or more of the 
below 
175 53 
Tetrabenazine 188 28 
Sulpiride 34 16 
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Haloperidol 66 19 
Olanzapine 156 49 
Tiapride 118 27 
Risperidone 98 51 
Quetiapine  45 8 
Group 1: Patients on antidopaminergic medication throughout the study. Group 2: Patients started on 
antidopaminergic medications part way through the study. *Some patients were on more than one of the drugs.  
 
 
Results 
 
Of the 5011 manifest HD patients included in our analysis, 2369 (42%) were taking antidopaminergic 
medication. These individuals were on average older, had been diagnosed with HD for longer, and 
were at a more advanced disease stage than those not taking antidopaminergic medication 
(supplementary table S1). After propensity score matching, there were no differences between the 
groups in terms of age, CAG repeat length, Total Functional Capacity score (TFC), time since 
diagnosis, educational level and DBS (p > 0.05, see Table 2). However, the group on 
antidopaminergic medication had significantly greater scores for both UHDRS total motor and total 
chorea scores, and for PBA depression, apathy and irritability scores (p < 0.001 for all). Importantly, 
aside from the total motor score, the differences between groups were small (around a 1-point 
difference). However, increased motor and psychiatric impairments in this group are expected, since 
these patients were specifically prescribed this medication to treat these symptoms (with 67% being 
prescribed for motor impairments and 28% for psychiatric impairments, see table S3). The 
antidopaminergic group also had a significantly lower composite total cognitive z- score than the non-
antidopaminergic group (p=<0.001, see table 2), and a lower raw score in all of cognitive tasks except 
Trail making A (see table S4), indicating worse performance. It is, therefore, important to note that 
the group on antidopaminergic medication appear to be at a similar disease stage but with have a more 
severe disease profile at baseline.  
 
Next, we selected a separate group of patients to investigate whether the introduction of 
antidopaminergic medication led to changes in motor, cognitive or psychiatric decline. Whilst this 
group also had a matched control group, the controls again had significantly less motor, psychiatric 
and cognitive impairment (see demographics table 3 and table S5). Therefore, whilst the control group 
can provide an indication of the expected change in score over the four-year time period in manifest 
HD patients, it comprises a somewhat clinically different group to those who start the medication. 
 
 
 
 7 
 
Table 2: Group 1. Demographics of participant groups at the first appointment, showing the mean 
with standard deviation in brackets and range below  
HD controls (non- 
antidopaminergic takers) 
(n= 466) 
HD antidopaminergic 
takers 
(n=466) 
Number of visits   3 (1) 
2-6 
3.1 (1) 
2-6 
Gender (m:f) 234:232 267:200 
ISCED 
(Educational level) 
3.6 (1.2) 
1-6 
3.5 (1.2) 
1-6 
Age 
(years) 
54.6 (9.7) 
26-79 
54.4 (9.2) 
26-79 
CAG repeat length 43 (2.1) 
40-55 
43.1 (2.1) 
40-55 
Disease burden score 
(DBS) 
394.4 (55) 
180-573.5 
397 (55.2) 
180-573.5 
Total Functional capacity score 
(TFC) 
9.9 (2.4) 
3-13 
9.3 (2.5) 
3-13 
Time since diagnosis 
(years) 
3.4 (3.7) 
0-22 
3.8 (3.7) 
0-22 
Total motor score UHDRS 
Max score 124 
 
28.1 (14.6) 
0-81 
 
33.8* (15.5) 
0-85 
Total chorea score UHDRS 
Max score 28 
8.2 (4.5) 
0- 26 
9.3* (5.2) 
0-28 
Irritability  
(PBA) 
Max score 32 
2.5 (3.9) 
0-25 
3.5* (5.1) 
0-28  
Depression 
(PBA) 
Max score 48 
4.3 (5.8) 
0-36 
5.7* (6.7) 
0-36  
Apathy 
(PBA) 
Max score 16 
2.2 (3.4) 
0-16 
3.7* (4.4) 
0-16  
MMSE 
Max score 30 
26.7 (2.7) 
14-30 
25.7* (3.3) 
11-30 
Composite cognitive Z-score 1.3 (5.3) 
-21.7 - 18.9 
-1.3 (5.8) 
-32.4 – 16.7 
*Indicates a significant difference (p<0.001) when compared with the control non-antidopaminergic 
medication group 
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Table 3. Group 2. Baseline demographics of participants having two assessments prior to and two 
assessments subsequent to starting antidopaminergic medication and matched controls. Showing the 
mean with standard deviation in brackets 
 Control group (those not 
taking dopamine 
medication but assessed at 
the same time points) 
(n=104) 
Pre and post antidopaminergic 
treatment group 
(n=90) 
Number of visits 4.4 (0.6) 
4-6 
4.3 (0.5) 
4-6 
Gender (m:f) 52:48 41:49 
ISCED 3.8 (1.2) 
1-6 
3.5 (1.2) 
2-6 
Age 52.6 (12) 
28-83 
53 (11.3) 
26-79 
CAG repeat length 42.9 (4.9) 
38-52 
43.4 (2.6) 
39-51 
Disease burden score (DBS) 388 (78.2) 
167.5-589 
392.9 (66.1) 
202.5-567 
Total Functional capacity score 
(TFC) 
Max score 13 
10.1 (3.2) 
0-13 
9.2 (3.2) 
0-13 
Time since diagnosis 
(years) 
4.1 (4.2) 
0-20 
 
4 (4) 
0-20 
Motor score (UHDRS) 
Max score 124 
28.1 (18.18) 
5-95 
31.3 (15.4) 
7-80 
Total Chorea score (UHDRS) 
Max score 28 
7.8 (4.9) 
0-21 
9.5* (5) 
0-21  
Irritability 
(PBA) 
Max score 32 
1.8 (2.8) 
0-13 
4.3*** (5.6) 
0-24 
Depression 
(PBA) 
Max score 48 
2.7 (3.9) 
0-18 
4.2* (5.5) 
0-23 
Apathy 
(PBA) 
Max score 16 
2 (3.7) 
0-16 
2.8 (4.1) 
0-16 
MMSE 
Max score 30 
27.5 (2.6) 
17-30 
26.3 (2.9) 
16-30 
Composite cognitive Z-score 1.5 (5.4) 
-11.2 - 15.8 
-1.7*** (4.8) 
-19.2 – 11.3 
*Indicates a significant difference (p<0.005) when compared with the control non- antidopaminergic 
medication group. ***Indicates a significant difference (p<0.001) when compared with the control non-
antidopaminergic medication group. 
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Group1 
HD antidopaminergic takers (n= 466) and HD controls (non- antidopaminergic takers) (n= 466) 
 
There was no difference in the annual change in UHDRS motor score between groups (F (1, 890) = 
8.359, P = 0.215), with antidopaminergic medication takers showing an average increase of 4.1 ± 
6.8 points per year and controls showing an average increase of 3.5 ± 7 points (see table 4 and figure 
1A). When each of the individual measures of the UHDRS motor score were considered, the 
antidopaminergic medication group exhibited a greater annual increase in their luria tristep score (P 
=0.002) and dysarthria (P =0.020) (data not shown), but a significantly smaller annual increase in 
chorea score when compared with those not on the treatment (0.4 ± 2.8 vs -0.1 ± 2.7 points, F (1, 895) 
= 8.674, P = 000, table 4 and figure 1B).  
 
Similarly, the antidopaminergic medication group displayed a significantly lower annual increase in 
the irritability score compared to non-takers (-0.4 ± 3.6 points vs 0.3 ± 3.1 points, F (1, 895) = 
8.674, P = 0.003) (see table 4 and figure 1C). In contrast, there were no differences between groups 
for depression (F (1, 905) = 0.178, P = 0.674) or apathy (F (1, 912) = 1.711, P = 0.391), see table 4. 
As this analysis included participants who scored zero for these measures, we repeated the analysis 
including only those prescribed the medication specifically for depression or apathy. There were still 
no differences in the rate of change between groups for either problem (data not shown).  
 
We next assessed the effect of antidopaminergic medication on cognitive performance (see table 4 for 
the composite cognitive z-score and S6 for the results of each individual cognitive task). HD patients 
taking antidopaminergic medication had a significantly lower z-score than non-takers (-0.8 ± 4.8 vs 
0.8 ± 3.5, F (1, 902) = 29.161, P < 0.001) indicative of greater impairment, see figure 1D. In terms of 
the individual cognitive tasks, the antidopaminergic group exhibited a greater decline in all tasks (P < 
0.001), except Trail making A score (P = 0.325). A multiple linear regression showed the degree of 
decline in composite cognitive z- score was significantly predicted by group (antidopaminergic takers 
versus non-takers), but not by gender, age, CAG repeat length, DBS, TFC, time since diagnosis, 
ISCED or by motor or psychiatric scores (F (12,878) = 3.439, p< 0.001, R2  = .045), see table 5.  
 
Finally, the antidopaminergic medication group had significantly greater decreases in UHDRS Total 
Functional Capacity Score (F (1, 896) = 32.993, P < 0.001) and UHDRS Independence score (F (1, 
895) = 8.482,  P = 0.004, see table 4), indicative of a greater annual loss in function and independence.  
 
The above pattern of results was also found when propensity matching was not performed and the two 
groups were compared using a Multivariate ANOVA with age, gender, CAG repeat length, DBS, TFC 
and time since diagnosis as the variables (see supplementary section, table S2). 
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Table 4: Group1. Average annual mean change in score for motor, psychiatric and cognitive 
measures per group (standard deviation in brackets)  
 Non-
antidopaminergic 
Medication 
Takers 
 
(n= 466) 
 
Antidopaminergic 
Medication 
Takers 
 
 
(n= 466) 
 
p 
 
Cohen’s 
d 
UHDRS total 
motor score 
 
3.5 
(6.8) 
4.1 
(7) 
0.215 
 
0.09 
UHDRS total 
chorea score 
 
0.4 
(2.7) 
 
-0.1* 
(2.8) 
0.004 
 
0.18 
Irritability 
(PBA) 
     
0.3 
(3.6) 
-0.4* 
(3.1) 
0.003 
 
0.21 
Depression 
(PBA) 
 
-0.2 
(4.1) 
-0.3 
(5) 
 
0.674 
 
0.02 
Apathy 
(PBA) 
 
0.3 
(2.7) 
0.5 
(3.4) 
0.391 
 
0.07 
Composite 
cognitive Z-
score 
0.8 
(3.5) 
-0.8*** 
(4.8) 
<0.001 
 
0.4 
Total Functional 
Capacity score 
(TFC) 
-0.5 
(1.4) 
 
-1*** 
(1.4) 
 
<0.001 
 
0.35 
UHDRS 
Independence 
scale 
-2.5 
(6) 
-3.8* 
(6.8) 
0.004 
 
0.2 
P- values are from a Univariate ANOVA with age and CAG as covariates.  *Indicates a significant 
difference (p<0.005) when compared with the control non- antidopaminergic medication group 
***Indicates a significant difference (p<0.001) when compared with the control non- antidopaminergic 
medication group 
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Table 5: Group1. Multivariate regression analysis showing factors associated with change in 
composite cognitive score.  
Predictor Variable Change in total cognitive Z-score 
B coefficient P 
Constant -1.689  0.781  
Group (antidopaminergic 
takers vs non 
antidopaminergic takers) 
-1.244  <0.001  
Age 0.046  0.071  
Gender 0.083  0.493  
CAG repeat length 0.094  0.430 
DBS -0.008  0.008  
TFC -0.039 
 
0.586 
 
Time since diagnosis  0.020 
 
0.619 
 
UHDRS total motor score 
 
-0.003 
 
0.813 
 
Depression (PBA) -0.012 
 
0.659 
 
Irritability (PBA) -0.059 
 
0.087 
 
Apathy (PBA) 0.030 
 
0.445 
 
ISCED  -0.155 0.183 
 
 
Group2 
Pre- and post-HD antidopaminergic takers (n= 90) and matched HD controls (non- 
antidopaminergic takers) (n= 108) 
 
Next, we selected a separate group of antidopaminergic medication takers with at least two 
assessments prior to starting the medication and two assessments after starting the medication (see 
table 6 and figure 2A-D). Onset of the medication led to a reduction in the average annual increase in 
UHDRS motor score (from 5.7 ± 11.2 points to 2.9 ± 9.2 points), which did not reach significance (t 
(74) = 1.178, P = 0.079).  This was because of a significantly reduced annual increase in UHDRS 
chorea score post medication (1.1 ± 4.7 points vs -0.5 ± 5.5 points, t (89) = 2.122, P = 0.037), (see 
table 6 and figure 2B as well as a significant decrease in saccade initiation (from a 0.6 ± 1.5-point 
increase to a 0.03 ± 1.7-point increase P = 0.020). In contrast, all other measures of UHDRS motor 
score remained stable pre and post medication (data not shown).  
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By comparison, the matched control group displayed no significant changes in motor (t (101) = 0.239, 
P = 0.265) or chorea scores (t (98) = 0.951, P = 0.344). Thus, whilst the antidopaminergic group 
showed significantly greater increases in motor score than the control group pre-medication (F (1, 
171) = 4.392, P = 0.038), they showed an equivalent rate of increase to controls post-medication (F 
(1, 169) = 0.012, P = 0.914, together with a significantly lower increase in chorea score (F (1, 183) = 
4.867, P = 0.029). 
 
There were, though, no differences found before or after onset of antidopaminergic medication in 
terms of depression (t (76) = 0.665, P = 0.508) or apathy (t (78) = 0.853, P = 0.0.396), see table 6. 
Similarly, the matched control group showed no significant change in these measures across the same 
time intervals. However, for irritability, whilst both groups had similar rates of decline during time 
interval 1, the group starting antidopaminergic medication displayed a strong trend for a reduced rate 
of increase post- medication (t (78) = 1.872, P = 0.065), which meant that they had a significantly 
lower average increase than the matched control group during time interval 2 (F (1, 175) = 10.061, P 
= 0.002), see figure 2C. 
 
Those prescribed antidopaminergic medication also showed a significant decrease in cognitive z score 
post medication, with a z-score of 0.8 ± 3.4 before medication and -0.7 ± 3.4, post-medication (t (76) 
= 3.332, P = 0.001), see table 6 and figure 2D. This was driven by a greater decline in the verbal 
fluency, Stroop word and interference and the Trail making B tasks (P < 0.05, see supplementary 
table S7), whereas there were no significant differences for SDMT, Stroop naming or Trail making A 
pre and post-medication (P > 0.05). In comparison, the matched controls displayed no change in z-
score or in any individual cognitive task over the time intervals (t (92) = 1.293, P = 0.199). 
 
Finally, for the antidopaminergic medication group, there were no differences in annual change in 
score pre or post- medication for TFC (t (80) = 0.435, P = 0.664) or Independence scales (t (80) = 
1.342, P = 0.184, table 6), suggesting that the medication did not directly impact on how the disease 
affects  functional capacity.  Similarly, the matched control group didn’t show any significant changes 
in annual progression of these measures at the different timepoints (see table 6).  
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Table 6: Group 2. Average annual mean change in score for pre and post antidopaminergic takers 
and matched controls (standard deviation in brackets) 
  
Control group 
(Time 1) 
(n=103) 
 
 
Control group 
(Time 2) 
        (n=103) 
 
p 
 
Cohen’s 
d 
Pre 
antidopaminergic 
medication 
(Time 1) 
        (n=90) 
 
Post 
antidopaminergic 
Medication 
(Time 2) 
(n=90) 
 
p 
 
Cohen’s 
d 
UHDRS total 
motor score 
 
2.4 
(7.9) 
2.7 
(7.6) 
0.819 
 
0.04 5.7 
(11.2) 
2.9 
(9.2) 
 
0.079 
 
0.27 
UHDRS total 
chorea score 
 
0.4 
(4.5) 
1 
(4.2) 
0.344 
 
0.14 1.1 
(4.7) 
 
-0.5* 
(5.5) 
0.036 
 
0.31 
UHDRS 
saccade 
initiation  
0.4 
(1.4) 
0.1 
(1.4) 
 
0.100 
 
0.21 0.6 
(1.5) 
0.03* 
(1.7) 
0.020 
 
0.35 
Irritability 
(PBA) 
 
0.4 
(4) 
0.6 
(3.4) 
0.745 
 
0.05 0.1 
(6.2) 
-1.8 
(6.2) 
 
0.065 
 
0.31 
Depression 
(PBA) 
 
-0.1 
(4.1) 
-0.1 
(4.5) 
0.962 
 
0 0.8 
(6.2) 
-0.2 
(6.7) 
 
0.508 
 
0.2 
Apathy 
(PBA) 
 
0.02 
(2.9) 
0.3 
(3.3) 
0.474 
 
0.09 0.3 
(4) 
0.9 
(4.9) 
 
0.396 
 
0.13 
Total 
Composite 
cognitive Z-
score 
0.4 
(3.9) 
-0.3 
(4) 
0.199 
 
0.18 0.8 
(3.4) 
-0.7*** 
(3.4) 
0.001 
 
0.44 
Total 
Functional 
Capacity 
score (TFC) 
-0.6 
(1.3) 
 
-0.4 
(1.6) 
 
0.483 
 
0.13 -0.9 
(1.8) 
-1 
(1.6) 
0.664 0.05 
UHDRS 
Independence 
scale 
          -3.1 
(7.6) 
         -1.8 
(9.5) 
0.3 0.15 -5.2 
(9.5) 
-3.6 
(7.3) 
0.183 0.18 
P-values are from paired t-tests. *Indicates a significant difference (p<0.005) when compared with 
the control non- antidopaminergic medication group. *** Indicates a significant difference (p<0.001) 
when compared with the control non- antidopaminergic medication group. 
 
 
 
Discussion 
 
This study interrogated the Enroll-HD database to investigate effects of antidopaminergic treatments 
on motor, cognitive and psychiatric function over a 3-year period.  
 
Effect of antidopaminergic medication on function and independence 
 
Those on antidopaminergic medication showed a greater annual decline in Total Functional Capacity 
and Independence scores than those who were not. However, seeing as there were no differences in 
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the rate of change in these measures following the onset of the antidopaminergic medication, this is 
unlikely to be a result of the dopaminergic medication itself, and may instead reflect the fact that this 
group had a more severe disease profile at baseline.  
 
Effect of antidopaminergic medication on motor features  
 
The annual increase in UHDRS chorea score over a 3-year period was, not surprisingly, significantly 
lower in HD patients taking antidopaminergic medication compared to HD patients who were not. 
Furthermore, HD patients beginning antidopaminergic medication part way through the study showed 
a significant 1.6-point reduction in chorea score on the UHDRS after starting the medication. This 
result is to be anticipated especially given the results of two clinical trials assessing tetrabenazine 
(TETRA- HD, Huntington Study Group 2006, [22]) and its modified form, detetrabenazine (FIRST- 
HD, Frank et al., 2016, [23]), which respectively showed a 3.5-point and 2.5-point reduction in 
UHDRS chorea score, after 12 weeks of treatment. The smaller reduction obtained in the current 
study may be explained by differences between the studies, e.g. differences in duration of treatment, 
sample population and most importantly our study looked at a number of different antidopaminergic 
medications (see table 1). 
 
In regard to the dopamine antagonists which are commonly prescribed off-label in HD,  
there have been a few small open-label studies which showed significant improvements in psychiatric 
measures but inconsistent motor effects, with some studies showing improvement [24-25], some 
stabilization [26] and some no change [27]. One open label study with olanzapine showed a 1.6-point 
reduction in UHDRS chorea score in 11 HD patients after 6 months [28], which is in line with our 
results. Our analysis is the first to assess the longitudinal effects of dopamine antagonists in a large 
sample of participants and provides evidence in support of their beneficial effect for the treatment of 
chorea in HD.  
 
Interestingly, we also found that antidopaminergic medication was associated with an improvement in 
saccade initiation deficits. It is well established that the basal ganglia controls the initiation of eye 
movements via inhibition of the superior colliculus [29]. However, evidence for a role of dopamine in 
this process in humans is lacking, although a correlation between the degree of striatal dopamine 
transporter (DAT) binding and the severity saccadic errors has been reported in patients with 
Parkinson’s disease [30]. Importantly, the current study suggests that the onset of antidopaminergic 
medication may improve saccade initiation in HD, but further work is needed to explore this.  
 
A recent retrospective analysis of the EHDN REGISTRY study showed that in contrast to our results, 
antidopaminergic medication takers had a greater annual increase in UHDRS total motor score 
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(including oculomotor dysfunction), compared to a control group [31]. The authors also showed that 
the annualised progression of chorea and dystonia did not differ between the groups. Crucially, the 
two groups weren’t matched on demographic or clinical variables, meaning that the antidopaminergic 
group were older, had a longer disease duration and also a higher disease burden score, and therefore 
a faster disease progression may have been expected. The fact that chorea and dystonia did not differ 
between the two groups, even in these circumstances, suggests that the antidopaminergic medication 
may have been of some benefit to these features of the disease. Our study suggests that if the groups 
were better matched, improvements in chorea and saccade initiation may have become apparent.   
 
Effect of antidopaminergic medication on psychiatric features  
 
HD patients on antidopaminergic medication showed a reduced annual increase in irritability scores 
compared to HD patients who were not, suggesting this medication may be beneficial in treating 
irritability in HD. These results support case studies highlighting the efficiency of olanzapine [28, 32-
33], risperidone [25] and quetiapine [26] in treating this aspect of HD. However, we found that these 
drugs did not appear to impact on annual changes in apathy or depression scores, suggesting that 
while the medication is not improving apathy it is also not making it worse. Theoretically, reducing 
levels of dopamine could lead patients to experience a reduction in their motivation and this given that 
apathy is a prominent feature of HD, these drugs might have been predicted to make this aspect of 
their symptomatology worse. This was not seen and is in line with a recent trial showing that 
bupropion was ineffective for treating this symptom [34]. However, randomised controlled trials 
(RCTs), which include detailed scales to assess these conditions are needed to more thoroughly 
explore the role of DA in depression and apathy in HD. 
 
Effect of antidopaminergic medication on cognitive features  
 
Assessment of the effects of antidopaminergic medication on the cognitive tasks performed in Enroll-
HD is of particular importance given the impact these problems have on quality of life. We found that 
HD patients on antidopaminergic medication had a more rapid annual cognitive decline than HD 
patients who were not. Studies of cognition in healthy individuals have also shown that DA 
antagonists can be detrimental to cognition [35-37]. Exactly why this should be the case is unclear, 
but it is known that dopamine modulates cognition in an inverted U function whereby both excessive 
and insufficient DA is detrimental to certain cognitive processes in healthy individuals [16] and thus it 
may be that these drugs in HD move patients away from their optimal dopamine level. 
 
Importantly, as this is an observational study, causality cannot be established, and it is possible that 
the differences viewed between the groups were driven by other unknown factors unrelated to DA or 
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the other variables we controlled for. Furthermore, there was innate bias in the dataset as those taking 
antidopaminergic had a more severe disease phenotype and therefore may represent a subgroup of HD 
with faster HD related cognitive deterioration, irrespective of medication- as we have reported 
previously [38-39].  
 
We sought to try and investigate this by looking at the speed of cognitive decline before and after 
antidopaminergic drugs were started. We found again that cognition worsened significantly in HD 
patients in the period subsequent to taking antidopaminergic medication for four of the seven 
cognitive tasks and this was not observed in the control group. Interestingly, two of these tasks (Trail 
making B and Stroop interference), require flexibility and set- shifting, processes known to be 
dependent on dopamine. However, whilst the tasks included in Enroll-HD are useful tools to obtain a 
basic indication of cognitive function, the battery was not designed specifically to be sensitive to DA 
dependent cognitive processes. Future research should study the effects of dopamine antagonism on 
cognition in HD in a more controlled manner, using tasks specific to the function of DA. 
 
The current study has a number of other limitations outside of the bias in terms of patient selection to 
the database. For example, scores on a particular day could be affected by a number of factors, such 
as tiredness, mood or other medications. Furthermore, some of the DA antagonists included in the 
study do not selectively act on DA receptors but also block other receptors, e.g., serotonin receptors. 
Since manipulations of serotonin have been shown to induce changes in cognitive functioning [40], it 
cannot be ruled out that the results of the current study were influenced by changes in levels of 
serotonin in addition to dopamine.  
 
Despite these drawbacks, this is the first study to assess the longitudinal effects of antidopaminergic 
medication on each of the major clinical aspects of HD. The results suggest that the medication is 
beneficial in treating chorea and irritability but may not influence apathy and depression. 
Antidopaminergic medication also appears to be associated with worsening cognition, which has 
important clinical implications since patients often report cognitive impairments to be more disruptive 
to daily life than motor disturbances. However, more controlled prospective studies are needed to 
fully elucidate the causative role of DA in cognitive impairments in HD and/or whether there are 
subtypes of disease that should be treated differently. 
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Figure 1. Graphs showing average annual change in UHDRS total motor score, PBA irritability and 
composite cognitive score per group.  
Group1. A. There is no difference in the annual increase in UHDRS total motor score between HD 
antidopaminergic medication takers and HD non-antidopaminergic medication takers. B. HD patients 
taking antidopaminergic medication had a significantly reduced increase in chorea score compared with 
HD controls not taking antidopaminergic medication. C. Antidopaminergic medication takers had a 
significantly smaller increase in reported irritability on the PBA compared to patients not on DA altering 
medications. D. HD antidopaminergic medication takers had a statistically faster rate of cognitive decline 
than HD patients not taking these drugs. Groups were compared using univariate analysis with age, CAG 
and gender as covariates. Mean and standard error of the mean are shown. *** p<0.001. n=466 per group.  
 
 
Figure 2. Graphs showing average annual change in UHDRS total motor score, PBA irritability and 
composite cognitive score per group. Group2. A. HD patients who had a period of assessment before 
being prescribed antidopaminergic medications did not show a significant difference in annual change in 
motor score pre- and post-antidopaminergic medication introduction. Matched controls also did not show a 
significant difference across the two time intervals. B. HD patients showed a diminished increase in chorea 
score in the period after they were prescribed the antidopaminergic medication. In contrast, matched 
controls did not show significant changes in chorea score between the two time intervals. C. The onset of 
antidopaminergic medication did not have a significant effect on PBA irritability scores. Matched controls 
also did not display significant changes in irritability score. D. HD patients who began antidopaminergic 
medication showed a significantly faster rate of cognitive decline in the period after medication 
introduction. In contrast, matched controls did not show any change in cognitive score. A paired t-test 
compared scores of time interval 1 (pre-antidopaminergic medication) with time interval 2 (post-
antidopaminergic medication). A univariate ANOVA compared scores of each group during each time 
interval with age, CAG, and gender as covariates. p<0.05. n= 81 pairs. 
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